These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30561745)

  • 1. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.
    Wang X; Wong SH; Wang XS; Tang W; Liu CQ; Niamul G; Wu B; Tam LS; Wu JCY; Chan FKL; Sung JJY; Ng SC
    Rheumatology (Oxford); 2019 May; 58(5):803-810. PubMed ID: 30561745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
    Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
    Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study.
    Chiu YM; Tang CH; Hung ST; Yang YW; Fang CH; Lin HY
    Scand J Rheumatol; 2017 May; 46(3):236-240. PubMed ID: 27766916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
    Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
    Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment.
    Sartori NS; Picon P; Papke A; Neyeloff JL; da Silva Chakr RM
    PLoS One; 2019; 14(12):e0224963. PubMed ID: 31790428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
    Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
    PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.
    Ge M; Man KK; Chui CS; Chan EW; Wong IC; Li X
    Drug Saf; 2019 Sep; 42(9):1091-1102. PubMed ID: 31168709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
    Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.
    Zhang Z; Fan W; Yang G; Xu Z; Wang J; Cheng Q; Yu M
    BMJ Open; 2017 Mar; 7(3):e012567. PubMed ID: 28336735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.